Bjoern Rosner carries an MS in Physics and a Ph.D. in Electrical Engineering. After innovating at the intersection of Nanotechnology and Pharmaceuticals for a decade, he joined Biogen 8 years ago to build and lead its Anti-Counterfeiting program and Global Serialization Programs. He has been overseeing the serialization program’s growth from the first project stage to a fully deployed solution supporting serialized production for most of Biogen’s commercial volumes. In 2020, Bjoern established a second element to the organization, an innovation function utilizing Agile methodology, to realize new digital solutions across Supply Chain and Commercial for the benefit of customers and patients.

Pop in the job: "Connecting people, working together and bringing innovation to operational life."

Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.